FGF21 mutants comprising a mutation at position 98, 171 and/or 180
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/18
C07K-014/50
A61K-038/00
출원번호
US-0167662
(2014-01-29)
등록번호
US-9493530
(2016-11-15)
발명자
/ 주소
Belouski, Edward John
Ellison, Murielle Marie
Hamburger, Agnes Eva
Hecht, Randy Ira
Li, Yue-Sheng
Michaels, Mark Leo
Sun, Jeonghoon
Xu, Jing
출원인 / 주소
Belouski, Edward John
인용정보
피인용 횟수 :
1인용 특허 :
79
초록▼
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
대표청구항▼
1. An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:4 or 8 with one or more substitutions, wherein the sequence is at least 85% identical to the amino acid sequence of SEQ ID NO: 4 or 8 and the one or more substitutions comprise (a) a substitution of: (i) the leucine residue at
1. An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:4 or 8 with one or more substitutions, wherein the sequence is at least 85% identical to the amino acid sequence of SEQ ID NO: 4 or 8 and the one or more substitutions comprise (a) a substitution of: (i) the leucine residue at position 98;(ii) the proline residue at position 171; or(iii) the alanine residue at position 180,wherein the substitution at position 98 is L98R, L98C, L98E, L98Q, L98K or L98T; the substitution at position 171 is P171A, P171R, P171N, P171D, P171C, P171E, P171Q, P171G, P171H, P171K, P171S, P171T, P171W or P171Y; and the substitution at position 180 is A180G, A180E, A180P or A180S; and(b) at least one substitution selected from (i) a cysteine mutation of Table 2;(ii) an engineered disulfide bond of Table 3;(iii) a stability enhancing mutation from Table 4;(iv) a proteolysis-resistant mutation from Table 5;(v) an aggregation mutation from Table 6;(vi) a C-terminal degradation mutation from Table 7;(vii) a glycosylation mutation from Table 8; and(viii) an O-glycosylation-resistant mutation selected form Table 9;wherein the at least one substitution is not at position 98 when the polypeptide comprises L98R, L98C, L98E, L98Q, L98K or L98T;wherein the at least one substitution is not at position 171 when the polypeptide comprises P171A, P171R, P171N, P171D, P171C, P171E, P171Q, P171G, P171H, P171K, P171S, P171T, P171W or P171Y;wherein the at least one substitution is not at position 180 when the polypeptide comprises A180G, A180E, A180P or A180S, andwherein said polypeptide is an FGF receptor agonist. 2. The isolated polypeptide of claim 1, wherein the cysteine mutation of (a) comprises a cysteine at a position selected from the group consisting of: 18-31, 33, 35-50, 54, 56-62, 64-73, 75-104, 106-135, 137-140, 152-154, 163 and 167. 3. The isolated polypeptide of claim 2, comprising an engineered disulfide bond comprises a pair of cysteine residues at one or more positions selected from the group consisting of: 19-138, 20-139, 21-33, 22-137, 22-139, 23-25, 23-28, 24-135, 25-122, 26-122, 27-123, 28-43, 28-124, 31-43, 33-21, 35-84, 41-82, 42-124, 42-126, 43-124, 50-69, 54-66, 58-62, 67-72, 67-135, 72-84, 73-93, 75-85, 75-92, 76-109, 77-79, 77-81, 80-129, 82-119, 94-110, 95-107, 100-102, 102-104, 115-117, 117-129, 117-130, 118-132, 118-134, 121-127, 123-125, 127-132, and 152-163. 4. The isolated protein of claim 1, comprises a D, E, R, K, H, S, T, N or Q at one or more positions selected from the group consisting of: 42, 54, 77, 81, 86, 88, 122, 125, 126, 130, 131, 139, 145, 146, 152, 154, 156, 161, 163, 170, and 172. 5. The isolated protein of claim 1, comprising: (a) Q, I or K at position 19;(b) H, L or F at position 20;(c) I, F, Y or V at position 21;(d) I, F or V at position 22,(e) A or R at position 150;(f) A or V at position 151;(g) H, L, F or V at position 152;(h) A, D, N, C, Q, E, P, or S at position 170;(i) A, R, N, D, C, E, Q, G, H, K, S, T, W or Y at position 171;(j) L or T at position 172; and(k) R or E at position 173. 6. The isolated protein of claim 1, comprising: (a) E, K or R at position 26;(b) E K, R, Q, or T at position 45;(c) T at position 52;(d) C, E or S at position 58;(e) A, E, K or R at position 60;(f) A, C, H or R at position 78;(g) C or T at position 86;(h) A, E, K, R or S at position 88;(i) C, E, K, Q, or R at position 98;(j) C, D, E, or R at position 99;(k) K or T at position 111;(l) D, E, H, K, N, R or Q at position 129; and(m) E, H, K or Y at position 134. 7. The isolated polypeptide of claim 1, comprising: (a) G, E, P or S at position 180;(b) G, P, K, T, A, L or Pat position 181; and(c) A P, G, S or A at position 179. 8. The isolated polypeptide of claim 1, comprising S167A, S167E, S167D, S167N, S167Q, S167G, S167V, S167H, S167K or S167Y. 9. The isolated polypeptide of claim 1, wherein the mutation at position 98 is L98R, the mutation at position 171 is P171G and the mutation at position 180 is A180E. 10. The isolated polypeptide of claim 1, further comprising (i) an N-terminal truncation of 8 or fewer residues;(ii) a C terminal truncation of 12 or fewer residues; or(iii) an N-terminal truncation of 8 or fewer residues and a C terminal truncation of 12 or fewer residues. 11. The isolated polypeptide of claim 10, wherein the polypeptide is capable of lowering blood glucose in a mammal. 12. The isolated polypeptide of claim 1, further comprising 1 to 10 amino acid residues fused to the C-terminus of the polypeptide. 13. The isolated polypeptide of claim 12, wherein the 1 to 10 amino acid residues are selected from the group consisting of glycine, proline and combinations thereof. 14. The isolated polypeptide of claim 1, wherein the polypeptide is covalently linked to one or more polymers. 15. The isolated polypeptide of claim 14, wherein the polymer is PEG. 16. A fusion polypeptide comprising the isolated polypeptide of claim 1 fused to a peptide that increases stability. 17. The fusion polypeptide of claim 16, wherein the peptide that increases stability is an IgG constant domain or fragment thereof. 18. The fusion polypeptide of claim 17, wherein the IgG constant domain comprises the amino acid sequence of SEQ ID NO:171 or SEQ ID NO:11. 19. The fusion polypeptide of claim 17, wherein the polypeptide is fused to the peptide that increase stability via a linker. 20. The fusion polypeptide of claim 19, wherein the linker is selected from the group consisting of polyalanines, (Gly)4 (SEQ ID NO:29), (Gly)5 (SEQ ID NO:30), (Gly)5-Ser-(Gly)3-Ser-(Gly)4-Ser (SEQ ID NO:28), (Gly)4-Ser-(Gly)4-Ser-(Gly)4-Ser (SEQ ID NO:31), (Gly)3-Lys-(Gly)4 (SEQ ID NO:32), (Gly)3-Asn-Gly-Ser-(Gly)2 (SEQ ID NO:33), (Gly)3-Cys-(Gly)4 (SEQ ID NO:34), Gly-Pro-Asn-Gly-Gly (SEQ ID NO:35), Gly-Ser(Gly4Ser)3 (SEQ ID NO:166), (Gly4Ser)4 (SEQ ID NO:167), (Gly4S)2 (SEQ ID NO:168), DAAAKEAAAKDAAAREAAARDAAAK (SEQ ID NO:169), and NVDHKPSNTKVDKR (SEQ ID NO:170). 21. A multimer comprising two or more fusion polypeptides of claim 20. 22. A pharmaceutical composition comprising the isolated polypeptide of claim 1 and a pharmaceutically acceptable formulation agent. 23. A method for reducing triglyceride levels, improving glucose tolerance, lowering blood glucose levels, or lowering insulin levels in a subject in need thereof comprising administering to the subject the pharmaceutical composition of claim 22. 24. The method of claim 23, wherein the subject has diabetes. 25. The method of claim 23, wherein the subject has obesity.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (79)
Bogin,Oren; Adar,Rivka; Yayon,Avner, Active variants of FGF with improved specificity.
Yayon,Avner; Rom,Eran; Thomassen Wolf,Elisabeth; Borges,Eric, Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof.
Kim Jin-Seok (Salt Lake City UT) Maruyama Atsushi (Yokohama JPX) Akaike Toshihiro (Tokyo JPX) Kim Sung Wan (Salt Lake City UT), Cationic polymer and lipoprotein-containing system for gene delivery.
Keifer, Michael C.; Valenzuela, Pablo D. T.; Barr, Philip J., Compositions comprising polynucleotides encoding human fibroblast growth factor receptor and uses thereof.
Keifer Michael C. (Clayton CA) Valenzuela Pablo D. T. (Berkeley CA) Barr Philip J. (Oakland CA), Expression and use of human fibroblast growth factor receptor.
Bergonzoni Laura (Milan ITX) Mazue Guy (Milan ITX) Isacchi Antonella (Milan ITX) Roncucci Romeo (Milan ITX) Sarmientos Paolo (Milan ITX), Extracellular form of the human fibroblast growth factor receptor.
Belouski, Edward John; Ellison, Murielle Marie; Hamburger, Agnes Eva; Hecht, Randy Ira; Li, Yue-Sheng; Michaels, Mark Leo; Sun, Jeonghoon; Xu, Jing, FGF21 polypeptides comprising two or more mutations.
Imamura, Toru; Asada, Masahiro; Suzuki, Masashi, Heparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Aebischer Patrick (Providence RI) Galletti Pierre M. (Providence RI) Panol George (Warwick RI) Miracoli Luigi (Genoa ITX), Implantable delivery system for biological factors.
Aebischer Patrick (Providence RI) Winn Shelley R. (Providence RI) Galletti Pierre M. (Providence RI), In vivo delivery of neurotransmitters by implanted, encapsulated cells.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Aslam Muhammed (Rochester NY) Light William (Victor NY), Method of making a projection viewable transparency comprising an electrostatographic toner image.
Roninson Igor B. (818 S. Laflin St. Chicago IL 60607) Holzmayer Tatyana (1451 W. Flournoy St. ; Apt. 2E Chicago IL 60607) Choi Kyunghee (1121 Albion St. ; Apt. 806 Denver CO 80220), Methods and applications for efficient genetic suppressor elements.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Benjamin Howard ; Chai Ling ; Findeis Mark A. ; Goodwin William ; Hundal Arvind ; Israel David I. ; Kelley Michael ; Keough Martin P. ; Lu Kuanghui ; Natoli Farah ; Peticolas Alicia ; Signer Ethan R., Peptide compounds useful for modulating FGF receptor activity.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Vegeto Elisabetta (7707 Eads Ave. LaJolla CA 92037) McDonnell Donald P. (10382 Rue Riviere Verte San Diego CA 92131) O\Malley Bert W. (629 Ramblewood Houston TX 77079), Progesterone receptor having C. terminal hormone binding domain truncations.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Bujard Hermann (Heidelberg DEX) Gossen Manfred (Heidelberg DEX) Salfeld Jochen G. (North Grafton MA) Voss Jeffrey W. (Framingham MA), Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.